Lv2
146 积分 2021-04-14 加入
Eltrombopag plus diacerein vs. eltrombopag in patients with ITP: a multicenter, randomized, open-label, phase 2 trial
5天前
已完结
Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study
20天前
已完结
SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial
23天前
已完结
A multicentre double‐blind, double‐dummy, randomised study of recombinant human thrombopoietin versus eltrombopag in the treatment of immune thrombocytopenia in Chinese adult patients
1个月前
已完结
Efficacy and safety of recombinant human thrombopoietin for the treatment of chronic primary immune thrombocytopenia in children and adolescents: A multicentre, randomized, double‐blind, placebo‐controlled phase III trial
1个月前
已完结
EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function
2个月前
已完结
Synergistic antitumor effect of combined EZH2 and DOT1L inhibition in B-cell lymphoma
2个月前
已完结
Targeting EZH2 for cancer therapy: From current progress to novel strategies
2个月前
已完结
Comparison of thrombopoietin receptor agonists plus recombinant human thrombopoietin vs. recombinant human thrombopoietin alone for hematopoietic reconstruction in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation
2个月前
已完结
Efficacy and Safety of Hetrombopag Versus Thrombopoietin in Promoting Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective, Multicenter, Randomized Controlled Clinical Trial
2个月前
已完结
皖公网安备34019202002308
